Table 1. Characteristics of Individuals 40 to 60 Years Old Recommended for Lipid-Lowering Treatment as Primary Prevention, Stratified by Benefit Level.
| Characteristic | Patients, No. (%) | ||
|---|---|---|---|
| 10-y Risk ≥7.5% | 10-y Benefit ≥2.3% | 30-y Benefit ≥15% | |
| Total study population | 212 (12.6) | 265 (15.7) | 307 (18.2) |
| Representation of US population | 5.4 million (9.5) | 7.3 million (13.0) | 9.9 million (17.5) |
| Age, median (interquartile range), y | 54 (53-55) | 54 (53-55) | 52 (51-53) |
| Women, No. (%) [95% CI] | 28 (13) [8-17] | 42 (16) [11-20] | 74 (24) [18-30] |
| Clinical findings, mean (95% CI) | |||
| Low-density lipoprotein cholesterol, mg/dL | 136 (130-142) | 143 (139-147) | 147 (144-150) |
| High-density lipoprotein cholesterol, mg/dL | 46 (44-49) | 47 (45-49) | 46 (44-47) |
| Triglycerides, mg/dL | 150 (132-169) | 153 (138-169) | 159 (147-172) |
| Systolic blood pressure, mm Hg | 134 (130-138) | 131 (127-134) | 129 (127-132) |
| Antihypertensive therapy, No. (%) [95% CI] | 68 (32) [21-43] | 74 (28) [19-36] | 95 (31) [22-39] |
| Cigarette smoking, No. (%) [95% CI] | 125 (59) [48-69) | 140 (53) [44-61) | 144 (47) [37-56] |
| Risk calculations, mean % (95% CI) | |||
| 10-y Risk | 10.6 (10.1-11.2) | 9.5 (8.9-10.1) | 7.9 (7.4-8.4) |
| 30-y Risk | 37.5 (35.4-39.6) | 35.6 (33.7-37.5) | 33.7 (32.2-35.1) |
| 30-y Absolute risk reduction | 22.1 (20.5-23.7) | 21.5 (20.1-22.8) | 20.6 (19.7-21.6) |
| 30-y Number needed to treat | (2.2-17.5) | (2.2-14.5) | (2.2-6.7) |
| Preventable cardiovascular events, mean (95% CI) | |||
| In 10 years | 204 000 (193 000-220 000) | 264 000 (242 000-279 000) | 296 000 (276 000-316 000) |
| In 30 years | 1 188 000 (1 102 000-1 275 000) | 1 577 000 (1 475 000-1 673 000) | 2 033 000 (1 945 000-2 132 000) |
SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259. To convert triglycerides to millimoles per liter, multiply by 0.0113.